Gefitinib (Iressa) in combo with chemoradiation in patients with locally advanced head & neck cancer

Study identifier:1839IL/0151

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I/II trial of ZD1839 (Iressa) given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer

Medical condition

Head and Neck Neoplasms

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Gefitinib, Cisplatin

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jun 2003
Primary Completion Date: -
Study Completion Date: 01 Mar 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria